CTI BioPharma Announces Presentations at the 63rd American Society of Hematology Meeting
SEATTLE, Nov. 4, 2021 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) today announced five poster presentations from the Company's pacritinib program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia, December 11-14, 2021.
The details of the poster presentations are as follows:
Abstract Title: A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia
Abstract title: Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia
Abstract Title: Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis
Abstract title: The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study
Abstract title: Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis
The full abstracts can be viewed here.
Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R, but not JAK1. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-presentations-at-the-63rd-american-society-of-hematology-meeting-301416611.html
SOURCE CTI BioPharma Corp.
Company Codes: NASDAQ-SMALL:CTIC